Clonal Hematopoiesis
Introduction
Clonal hematopoiesis (CH) is a condition characterized by the expansion of specific blood cell lineages originating from a single hematopoietic stem cell (HSC). [1] This phenomenon is commonly observed with aging [2] and can involve driver mutations, making it ubiquitous in healthy adults . [3], [4]
Biological Basis
The underlying biological mechanism of clonal hematopoiesis involves the accumulation of somatic alterations in the DNA of hematopoietic stem cells. [2] These alterations can arise from mitotic errors or DNA damage. When such an alteration confers a selective growth advantage to a particular HSC, it can lead to the preferential expansion of that cell and its progeny, forming a clone. [2] Key genes frequently implicated in clonal hematopoiesis include DNMT3A and TET2, which often dominate clonal expansion and demonstrate distinct genetic predispositions . [5], [6] Other genes, such as ASXL1, TP53, PPM1D, ATM, LY75, CD164, GSDMC, SETBP1, TCL1A, PARP1, SMC4, TMEM209, ENPP6, and ZBTB33, are also associated with various clonal hematopoietic phenotypes.
Clinical Relevance
Clonal hematopoiesis is clinically relevant due to its association with an increased risk of several adverse health outcomes. It is linked to a heightened risk of hematological neoplasms, including myeloid leukemias, as well as cytopenias, cardiovascular disease (CVD), infection, and all-cause mortality . [2], [7] Specifically, DNMT3A-linked CH has been associated with the subsequent development of myeloid leukemias. [2] Beyond hematological cancers, CH has been found to increase the risk of atherosclerotic cardiovascular disease [8] acute kidney injury [9] chronic obstructive pulmonary disease [10] and chronic liver disease. [11] Furthermore, therapy-related CH is common in patients with non-hematologic cancers and is associated with adverse clinical outcomes, including after autologous stem-cell transplantation for lymphoma . [12], [13] Hematopoietic mosaic chromosomal alterations, a form of CH, also increase the risk for diverse types of infection. [14]
Social Importance
The identification of clonal hematopoiesis and its genetic underpinnings holds significant social importance. Understanding the germline and somatic causes of CH has the potential to improve knowledge of the initiating events in the development of common diseases. [2] Given its prevalence, particularly in the elderly, and its links to aging, inflammation, and a range of chronic conditions, CH represents a crucial area of research for public health . [15], [16] Insights into CH could lead to earlier risk stratification, targeted prevention strategies, and novel therapeutic approaches for a variety of age-related and inflammatory diseases.
Methodological and Phenotypic Definition Challenges
Studies on clonal hematopoiesis (CH) face methodological and statistical constraints that can impact the robustness of findings. While large biobank-scale studies are beneficial for broad assessments, analyses of specific CH subtypes often suffer from lower sample sizes, potentially limiting statistical power and increasing the risk of effect-size inflation. [17] Furthermore, the reliance on single-time-point measurements, without serial sampling, restricts the ability to fully understand the evolutionary dynamics of CH clones or establish clear causal relationships over time. [2] This snapshot view makes it challenging to differentiate transient clonal expansions from stable, progressive CH.
Accurate phenotypic definition and measurement also present significant hurdles. There is a potential for misclassification, where true germline variants might be erroneously identified as somatic clonal hematopoiesis variants, or vice-versa, particularly for variants with high variant allele frequencies. [2] Additionally, the definition of CHIP (clonal hematopoiesis of indeterminate potential) can involve complex criteria, and simplified definitions, while increasing sample size, might compromise the exclusivity of mutations in specific driver genes. [2] When assessing clinical outcomes, dependence on administrative data such as ICD10 codes, hospital records, and self-reported information can introduce heterogeneity and potential inaccuracies in phenotype assignment. [2]
Ancestry, Generalizability, and Replication Gaps
A critical limitation in understanding clonal hematopoiesis is the challenge of generalizability across diverse populations and ancestral backgrounds. Research indicates significant ancestry-specific effects on CH development, with studies observing varying frequencies of CH between cohorts of different ancestries, such as the Mexico City Prospective Study and the UK Biobank. [18] This suggests that findings from predominantly European populations may not be directly transferable or fully representative of CH prevalence and mechanisms in other ethnic groups. [18] Consequently, while novel genetic signals are identified, their consistency and relevance across a multi-ancestry landscape require further comprehensive investigation.
The limited exploration of genetic ancestry's full impact on CH contributes to replication gaps and potentially biased interpretations of risk factors and associations. Associations identified in one ancestral group, such as previously reported links from European populations, may not consistently replicate in others, highlighting the need for more inclusive and diverse cohorts. [18] Such disparities underscore the importance of conducting studies in varied populations to uncover unique genetic and environmental interactions that might modulate CH susceptibility and progression in different ancestral contexts. Without broader representation, the full spectrum of CH etiology and its clinical implications remains incompletely understood.
Environmental Confounders and Unexplained Heritability
Environmental factors and gene-environment interactions represent substantial confounders in CH research. Studies have demonstrated clear associations between modifiable lifestyle factors, including sedentary habits, high-fat diets, tobacco smoke, and alcohol intake, and their impact on hematopoietic stem cell niches and CH development . [19], [20] For instance, ASXL1 mutations, a common CH driver, are strongly linked to smoking. [21] Furthermore, therapy-related clonal hematopoiesis, induced by prior cancer treatments, is a prevalent phenomenon in patients with non-hematologic cancers and is associated with adverse clinical outcomes, making it difficult to distinguish from spontaneous, age-related CH in observational studies . [12], [13]
Despite significant advances in identifying genetic predispositions, a considerable portion of the heritability of clonal hematopoiesis remains unexplained. The estimated narrow-sense heritability for CH is relatively low, around 3.57%, indicating that common genetic variants account for only a small fraction of the observed variability. [17] This "missing heritability" suggests that either rare genetic variants, complex epigenetic mechanisms, or unmeasured environmental exposures and their intricate interactions play a more substantial role than currently understood. [17] The complex interplay between CH, inflammation, and various comorbidities further complicates the elucidation of direct causal pathways and underlying biological mechanisms. [22] A lack of experimental data to fully characterize the mechanisms behind novel associations also represents a knowledge gap. [2]
Variants
Germline genetic variants play a significant role in predisposing individuals to clonal hematopoiesis (CH), a condition characterized by the expansion of specific blood cell lineages that increases the risk of hematologic malignancies and other age-related diseases. These variants often affect genes involved in critical cellular processes such as telomere maintenance, DNA repair, and hematopoietic stem cell regulation. Understanding these genetic predispositions is crucial for identifying individuals at higher risk and elucidating the underlying mechanisms of CH development.
Variants in genes critical for telomere maintenance and DNA repair pathways are strongly linked to clonal hematopoiesis. For instance, the TERT gene, which encodes the catalytic subunit of telomerase, an enzyme vital for maintaining telomere length, is associated with several variants. rs7705526, rs2853677, and rs13156167 are located in the 5p15.33 region containing TERT and have been identified in genome-wide association studies related to CH. [17] The minor alleles of TERT variants, such as rs7705526_A and rs2853677_G, can have varying effects on CH and leukocyte telomere length (LTL), suggesting complex regulatory roles. [1] Acquired alterations in TERT can enable hematopoietic stem cells to bypass replicative exhaustion, a key step in clonal expansion. [1] Similarly, variants in ATM (Ataxia Telangiectasia Mutated), such as rs611646, are relevant due to ATM's central role in the DNA damage response pathway. ATM is a known CH-related gene, and its dysfunction can lead to genomic instability, thereby promoting the accumulation of somatic mutations and the emergence of clonal hematopoiesis. [23]
Other variants influence the regulation and proliferation of hematopoietic cells. The rs2887399 variant, located upstream of the TCL1A gene on chromosome 14q32.13, is one such example. This minor allele (rs2887399_T) is associated with a protective effect against CH and is reported to suppress the ectopic expression of TCL1A in specific hematopoietic stem cells, thereby mitigating aberrant stem cell expansion. [1] TCL1A itself is a proto-oncogene whose aberrant activation can promote stem cell expansion in clonal hematopoiesis. [1] Variants in CD164 (sialomucin core protein 24), including rs11753645 and rs35452836, also play a role, with lead alleles at this locus exhibiting opposing effects on DNMT3A- and TET2-mutant CH, and being specifically associated with small rather than large clones. [17] Additionally, the rs1849209 variant, located in the vicinity of LINC01478 and SETBP1-DT, is indirectly linked to SETBP1, a gene whose somatic mutations are known drivers of myeloid malignancies and are associated with increased risk of DNMT3A-CH. [17]
Long non-coding RNAs (lncRNAs) and genes involved in less common pathways also contribute to CH susceptibility. The rs187319135 variant in LINC02318 (previously referred to as TCL1B upstream) has been shown to confer risk to overall and gene-specific clonal hematopoiesis, with the T allele increasing this risk. [18] LncRNAs like LINC02318 can modulate gene expression and cellular processes, impacting hematopoietic stem cell fate. Variants affecting THRB (Thyroid Hormone Receptor Beta) and its antisense RNA, THRB-AS2, such as rs869785, may influence hematopoietic cell differentiation and proliferation through thyroid hormone signaling. Although specific mechanisms are still being explored, genetic variations in genes like IFT80 and TRIM59-IFT80 (rs4616688, rs201009932, rs9799314) and POGLUT3 (rs11212676, rs11212666, rs10749918) could affect cellular processes such as ciliary function, protein modification, or immune regulation, thereby indirectly influencing the fitness and clonal expansion of hematopoietic stem cells.
Key Variants
| RS ID | Gene | Related Traits |
|---|---|---|
| rs7705526 rs2853677 rs13156167 |
TERT | leukocyte quantity platelet crit neutrophil count, eosinophil count granulocyte count neutrophil count, basophil count |
| rs2887399 | TCL1A - TUNAR | mosaic loss of chromosome Y measurement clonal hematopoiesis platelet crit myeloproliferative disorder chromosome, telomeric region length |
| rs4616688 rs201009932 |
IFT80, TRIM59-IFT80 | low density lipoprotein cholesterol measurement clonal hematopoiesis |
| rs11753645 rs35452836 |
CD164 | clonal hematopoiesis |
| rs1849209 | LINC01478 - SETBP1-DT | aging platelet volume sh2 domain-containing protein 1a measurement clonal hematopoiesis |
| rs9799314 | TRIM59-IFT80, IFT80 | glucose measurement clonal hematopoiesis |
| rs187319135 | LINC02318 | clonal hematopoiesis |
| rs11212676 rs11212666 rs10749918 |
POGLUT3 | clonal hematopoiesis |
| rs611646 | ATM | clonal hematopoiesis |
| rs869785 | THRB-AS2, THRB | monocyte count red blood cell density clonal hematopoiesis mean corpuscular hemoglobin concentration erythrocyte volume |
Defining Clonal Hematopoiesis
Clonal hematopoiesis (CH) is fundamentally defined as the clonal expansion of a blood stem cell and its progeny, driven by acquired somatic driver mutations. [17] This process results in a substantial proportion of mature blood cells within an individual being derived from a single hematopoietic stem cell lineage. [1] While often associated with aging, CH is increasingly recognized for its association with various adverse health outcomes. [2]
A crucial conceptual distinction in the definition of CH is its exclusion of established hematological malignancies. The definition of CH specifically omits pathological expansions characteristic of defined, committed lineages such as lymphomas, leukemias, myelodysplastic syndromes (MDS), and myeloproliferative neoplasms (MPN). [1] This framework positions CH as a pre-malignant or benign condition of clonal expansion, setting it apart from overt hematologic cancers.
Diagnostic Criteria and Measurement
The detection of clonal hematopoiesis primarily relies on identifying somatic driver mutations using advanced sequencing technologies, such as whole-genome sequencing (WGS) or exome sequencing. [1] Operational definitions for Clonal Hematopoiesis of Indeterminate Potential (CHIP) frequently incorporate a threshold for Variant Allele Frequency (VAF), with some research defining CHIP as the presence of a mutation with a VAF of 0.1 or greater. [2] This VAF threshold helps distinguish true clonal expansions from background noise or low-level mutations.
Research criteria for including individuals in studies of CH often involve stringent exclusion parameters to ensure the studied population does not have an existing hematological disorder. These criteria typically exclude participants with a diagnosis of specific hematological disorders (e.g., International Classification of Diseases, Tenth Revision (ICD10) codes C81-C96 and D45-D47) before or within a defined period after blood draw. [1] Additionally, individuals with significant abnormalities in hematology parameters, such as white blood cell counts outside a normal range (<1.5 × 10^9 or >35 × 10^9 cells per liter), low hemoglobin concentration (<8 g/dl), or low platelet count (<50 × 10^9 cells per liter), are often excluded to differentiate CH from overt blood disorders. [1]
Classification and Subtypes
Clonal hematopoiesis can be broadly classified as "overall CH," which encompasses any qualifying clonal expansion, or into more specific subtypes based on the underlying somatic driver mutations. [17] Gene-specific classifications are prevalent, identifying CH by mutations in key genes such as DNMT3A, TET2, ASXL1, or various splicing factors. [17] For example, individuals designated as "DNMT3A carriers" are defined by having at least one somatic mutation in the DNMT3A gene without mutations in other specified CH genes. [2]
Beyond specific gene mutations, CH can also be categorized by the size of the clonal expansion, distinguishing between "large clone CH" and "small clone CH," which may carry different clinical implications or genetic predispositions. [17] Furthermore, other distinct clonal hematopoietic phenotypes, such as mosaic loss of chromosome Y (mLOY), mosaic loss of chromosome X (mLOX), and mosaic autosomal chromosomal alterations (mCAaut), are recognized. These can be studied as non-overlapping phenotypes to understand their unique characteristics and shared genetic risk factors with CHIP. [2]
Clinical Significance and Associated Terminology
The term Clonal Hematopoiesis of Indeterminate Potential (CHIP) represents a critical diagnostic and prognostic concept within the field, referring to the presence of clonal hematopoiesis without an overt, diagnosed hematological malignancy. [2] While individuals with CHIP are often asymptomatic, the condition is a significant indicator of an increased risk for various adverse health outcomes, including the development of hematologic malignancies and cardiovascular disease (CVD). [2]
The clinical relevance of CH extends to an elevated risk for other serious conditions, such as chronic kidney disease, acute kidney injury, chronic obstructive pulmonary disease, and chronic liver disease. [18] Research also investigates related terminology like "barcode-CH" in specific analytical contexts, and explores germline genetic contributions and environmental factors, such as smoking, as important modifiers or risk factors influencing CH phenotypes and their associated health impacts. [1]
Causes of Clonal Hematopoiesis
Clonal hematopoiesis (CH) is a condition characterized by the expansion of blood cell lineages derived from a single hematopoietic stem cell (HSC) that has acquired advantageous somatic mutations [2] The development of CH is a multifactorial process influenced by a complex interplay of genetic predispositions, environmental exposures, age-related cellular changes, epigenetic alterations, and co-existing medical conditions.
Genetic Predisposition and Somatic Mutations
The primary cause of clonal hematopoiesis is the acquisition of somatic mutations in hematopoietic stem cells that confer a selective growth advantage, leading to the expansion of particular cell lineages [2] Key driver genes frequently mutated in CH include DNMT3A, TET2, ASXL1, and TP53 [5] Beyond these somatic events, germline genetic factors play a significant role in predisposing individuals to CH. Large-scale studies have identified both common and rare inherited variants that contribute to CH phenotypes, highlighting a substantial polygenic basis [2] For instance, germline variants in genes such as ATM, LY75, CD164, and GSDMC have been associated with both CHIP (Clonal Hematopoiesis of Indeterminate Potential) and mosaic loss of the Y chromosome (mLOY), suggesting shared genetic risk factors [2] Furthermore, gene-gene interactions, like the aberrant activation of TCL1A, can promote stem cell expansion, illustrating complex genetic pathways that contribute to clonal outgrowth [24]
Environmental Triggers and Lifestyle Factors
Environmental exposures and lifestyle choices are critical external factors that can influence the incidence and progression of clonal hematopoiesis [19] A sedentary lifestyle, high-fat diet, tobacco smoke, and alcohol intake have all been shown to impact the hematopoietic stem cell niches, potentially creating an environment conducive to clonal expansion [20] Smoking, in particular, is strongly associated with the presence of ASXL1 mutations in CH and is a significant risk factor for lung cancer in patients with CH mutations [21] Genetic variants on chromosome 15q25, linked to objective measures of tobacco exposure, further underscore the interplay between genetics and environmental influences in CH development [25] Geographic and ancestry-specific effects also contribute, with studies showing clonal hematopoiesis to be significantly less common in populations with predominantly non-European ancestry, and its frequency positively correlating with the proportion of European genetic ancestry [18] These findings suggest that diverse external stimuli can act as selective pressures, favoring the expansion of mutated hematopoietic clones.
Age-Related Dynamics and Epigenetic Mechanisms
Age is the most prominent risk factor for clonal hematopoiesis, with somatic alterations progressively accumulating in hematopoietic stem cells over an individual's lifespan [2] These age-related mitotic errors and DNA damage provide the substrate for mutations that can confer a selective advantage, leading to the expansion of specific cell lineages. Concurrently, epigenetic mechanisms play a crucial role, particularly through genes frequently mutated in CH, such as DNMT3A and TET2 [5] DNMT3A encodes a DNA methyltransferase responsible for establishing and maintaining DNA methylation patterns, while TET2 is involved in the active demethylation of DNA. Mutations in these genes can disrupt normal epigenetic regulation, altering gene expression and conferring a fitness advantage to affected hematopoietic stem cells, thereby driving clonal expansion [26] The Tcl1 protein, known to inhibit de novo DNA methylation, also highlights the broader epigenetic landscape influencing clonal dynamics.
Comorbidities and Therapy-Related Influences
Clonal hematopoiesis is increasingly recognized as a condition that not only reflects aging but also predisposes individuals to a wide range of adverse health outcomes and comorbidities [2] It is associated with an increased risk of hematological neoplasms, cytopenias, cardiovascular disease (CVD), diverse types of infection, chronic kidney disease, acute kidney injury, chronic obstructive pulmonary disease, and chronic liver disease [2] Beyond spontaneous development, prior cancer therapies, including chemotherapy and radiation, are significant contributors to therapy-related CH. These treatments can induce somatic mutations and promote the expansion of pre-existing or newly acquired clonal populations in hematopoietic stem cells [12] Mutations in genes like PPM1D and TP53 are particularly implicated in therapy-related CH and are linked to cancer predisposition and the development of therapy-related acute myeloid leukemia [27] Furthermore, inflammation is a key partner in both the leukemogenesis and comorbidity profiles associated with clonal hematopoiesis [22]
Biological Background of Clonal Hematopoiesis
Clonal hematopoiesis (CH) is a condition characterized by the expansion of blood cells derived from a single hematopoietic stem cell (HSC) lineage, which has acquired specific somatic mutations . [1], [2] These mutated cells gain a competitive advantage, leading to their disproportionate representation within the circulating blood cell populations. [2] While often asymptomatic, CH is increasingly recognized as a precursor to various hematological and systemic diseases, particularly with advancing age . [2], [3], [7]
Hematopoietic Stem Cell Dynamics and Clonal Expansion
The foundation of clonal hematopoiesis lies within the hematopoietic stem cell compartment, the primary source of all mature blood cells in adults. [28] These multipotent stem cells reside mainly in the bone marrow and continuously generate new blood cells through a process called hematopoiesis, ensuring the replenishment of various lineages, including red blood cells, white blood cells, and platelets. Over an individual's lifetime, HSCs accumulate somatic alterations in their DNA, primarily due to mitotic errors during cell division and exposure to DNA damaging agents. [2] When these alterations occur in specific "driver" genes and confer a selective growth advantage, the affected HSC can outcompete its neighbors, leading to the expansion of its progeny and the establishment of a clonal population . [1], [2] This clonal expansion can involve multiple blood cell lineages, including lymphocytes, although myeloid lineages are often more directly linked to the underlying HSC population. [1]
Genetic and Epigenetic Drivers of Clonal Dominance
The emergence and expansion of clonal hematopoiesis are primarily driven by acquired somatic mutations in key genes that regulate cell growth, survival, and differentiation. Among the most frequently mutated genes are DNMT3A and TET2, which are central to epigenetic regulation, specifically DNA methylation. [5] Mutations in DNMT3A and TET2 can alter the epigenetic landscape of hematopoietic cells, affecting gene expression patterns and conferring a fitness advantage, although they can also exhibit distinct impacts on hematopoietic progenitor cell fitness . [26], [29] Other significant driver mutations include those in ASXL1, which is strongly associated with environmental factors like smoking, and the proto-oncogene TCL1A, whose aberrant activation promotes stem cell expansion . [21], [24] Mutations in tumor suppressor genes like TP53 and PPM1D are also implicated, alongside variants in genes such as ATM, LY75, CD164, GSDMC, SETBP1, ZBTB33, and GNASR201C, all of which contribute to the complex genetic landscape underlying clonal hematopoiesis and its associated phenotypes . [2], [11], [26], [27]
Molecular and Cellular Pathway Dysregulation
The somatic mutations found in clonal hematopoiesis exert their effects by disrupting critical molecular and cellular pathways within hematopoietic stem and progenitor cells. For instance, mutations in DNMT3A and TET2 directly impact DNA methylation patterns, a crucial epigenetic modification that controls gene expression, with Tcl1 protein also known to inhibit de novo DNA methylation in certain contexts. [2] Beyond epigenetic modifiers, aberrant activation of the TCL1A proto-oncogene can promote the expansion of stem cell populations, tipping the balance towards clonal dominance. [24] Signaling pathways, such as those involving Interleukin-6 (IL-6), play a role, with genetic variations affecting IL-6 signaling shown to modulate the cardiovascular risk associated with CH . [9], [30] Other pathways, including the Hedgehog and mutant FLT3 signaling in myeloid leukemia or the HIF network and hub gene EPAS1 in lung adenocarcinoma, illustrate how these genetic alterations can integrate into complex regulatory networks to influence cell fate, proliferation, and differentiation, ultimately leading to the observed clonal expansion and its broader health implications. [31]
Pathophysiological Consequences and Systemic Disease Associations
Clonal hematopoiesis, particularly with increasing age, is not merely an isolated blood disorder but rather a systemic condition with far-reaching pathophysiological consequences . [2], [7] It significantly elevates the risk for various hematological neoplasms, including acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) . [2], [32] Beyond cancer, CH is a strong independent risk factor for cardiovascular disease (CVD), including atherosclerotic cardiovascular disease, and is implicated in the progression of chronic ischemic heart failure. [7] The underlying mechanism often involves a chronic inflammatory state, which is enhanced by clonal cells and acts as a partner in both leukemogenesis and other comorbidities, connecting aging and inflammation in diseases like CVD. [22] Furthermore, CH has been associated with an increased risk of diverse types of infections, cytopaenias, chronic kidney disease, acute kidney injury, chronic obstructive pulmonary disease, and chronic liver disease, highlighting its broad impact on organ-level biology and overall systemic health . [9], [10], [11], [14], [21] The presence of therapy-related clonal hematopoiesis in patients undergoing treatment for non-hematologic cancers also correlates with adverse clinical outcomes, and CH can worsen outcomes following autologous stem-cell transplantation for lymphoma . [12], [13]
Environmental and Lifestyle Modulators
Environmental and lifestyle factors play a significant role in influencing the development and progression of clonal hematopoiesis, impacting the hematopoietic stem cell niches where these processes unfold . [19], [20] A sedentary lifestyle, high-fat diet, tobacco smoke, and alcohol intake are recognized as contributors to the alterations within these crucial bone marrow environments. [20] Notably, smoking has a particularly strong association with specific driver mutations, such as those in the ASXL1 gene. [21] Genetic variants on the chromosome 15q25 locus, for instance, are linked to objective measures of tobacco exposure, indicating a genetic predisposition that interacts with environmental insults. [25] These external influences can exacerbate DNA damage, promote selective pressures, and accelerate the clonal expansion of mutated hematopoietic stem cells, thereby increasing an individual's risk for CH and its associated adverse health outcomes.
Epigenetic Modifiers and Transcriptional Control
Clonal hematopoiesis (CH) often originates from somatic mutations in genes that regulate epigenetic processes, fundamentally altering gene expression patterns within hematopoietic stem and progenitor cells (HSPCs). Key driver mutations include those in DNMT3A and TET2, which are crucial for DNA methylation and demethylation, respectively. DNMT3A mutations lead to aberrant DNA methylation, while TET2 mutations impair the conversion of 5-methylcytosine to 5-hydroxymethylcytosine, both disrupting normal epigenetic landscapes and contributing to the selective advantage of mutant clones. [5] Additionally, mutations in ASXL1, which encodes a component of the polycomb repressive complex 1, and aberrant activation of the proto-oncogene TCL1A also play significant roles in transcriptional dysregulation. Specifically, TCL1A activation promotes the expansion of stem cells, indicating its direct involvement in driving clonal growth. [24] These genetic alterations lead to altered chromatin states and differential gene expression, thereby influencing cell fate decisions, proliferation, and survival in the hematopoietic system. [32]
Inflammatory Signaling and Microenvironmental Crosstalk
The hematopoietic microenvironment and systemic inflammatory signals are critical modulators of clonal expansion. Chronic inflammation, for instance, is recognized as a partner in both leukemogenesis and the comorbidities associated with clonal hematopoiesis. [22] Signaling pathways involving cytokines, such as interleukin-6 (IL-6), have been implicated, with genetic deficiencies in IL-6 signaling shown to attenuate cardiovascular risk in individuals with CH. [30] Beyond endogenous signals, environmental factors significantly influence the hematopoietic stem cell niches and promote clonal outgrowth; these include sedentary lifestyles, high-fat diets, tobacco smoke, and alcohol intake. [20] For example, ASXL1 mutations are strongly associated with smoking, highlighting how external stressors can select for specific mutant clones and foster their expansion through complex pathway crosstalk within the bone marrow niche. [21]
Cellular Fitness and Proliferative Advantage
The defining characteristic of clonal hematopoiesis is the selective advantage conferred by driver mutations, enabling the expansion of mutant hematopoietic stem and progenitor cells. Mutations in genes such as DNMT3A and TET2 lead to divergent effects on hematopoietic progenitor cell fitness, often enhancing their proliferation and survival capabilities compared to wild-type cells. [26] This increased fitness, driven by enhanced proliferative capacity and altered cellular processes, supports sustained clonal expansion and outcompetes normal hematopoiesis, particularly under conditions of stress or aging. [7] The acquisition of these advantageous traits allows clonal cells to more efficiently utilize resources and evade normal homeostatic controls, thereby increasing their representation in the blood cell repertoire.
Systems-Level Dysregulation and Disease Pathogenesis
The dysregulation originating from clonal hematopoiesis extends beyond the hematopoietic system, contributing to a range of adverse health outcomes through intricate systems-level interactions. CH is associated with an increased risk of atherosclerotic cardiovascular disease, diverse types of infection, chronic kidney injury, chronic liver disease, and chronic obstructive pulmonary disease. [7] These widespread effects arise from pathway dysregulation in clonal cells that influence systemic inflammation, immune responses, and tissue repair mechanisms. The emergent properties of an expanded clonal population, characterized by altered cellular functions and interactions, thus contribute to the pathogenesis of these comorbidities, emphasizing CH as a systemic risk factor rather than solely a hematologic condition. [33]
Clinical Relevance of Clonal Hematopoiesis
Clonal hematopoiesis (CH) is characterized by the expansion of specific blood cell lineages originating from a single hematopoietic stem cell that has acquired a somatic mutation. While often associated with aging, CH has significant clinical implications extending beyond its prevalence in the elderly population, serving as a critical indicator for various disease risks and influencing patient management strategies. Research leveraging large-scale genomic analyses has elucidated its role in predicting disease progression, informing risk stratification, and highlighting associations with a spectrum of comorbidities. [17]
Prognostic Indicator for Hematologic Malignancies and Treatment Outcomes
Clonal hematopoiesis serves as a significant prognostic marker, particularly for the development and progression of hematologic malignancies. The presence of specific somatic mutations associated with CH can precede the diagnosis of acute myeloid leukemia (AML) by several years, offering a window for early risk assessment in healthy individuals. [34] Beyond AML, CH is linked to an elevated risk for other hematologic disorders such as myelodysplastic syndromes (MDS), chronic myeloid leukemia (CML), myelofibrosis, polycythemia vera, essential hemorrhagic thrombocythemia, monocytic leukemia, and aplastic anemia. [2] Furthermore, CH can impact treatment outcomes in oncology settings; for instance, therapy-related clonal hematopoiesis in patients with non-hematologic cancers is common and associated with adverse clinical outcomes, and CH is linked to adverse outcomes following autologous stem-cell transplantation for lymphoma. [12] Certain mutations, such as PPM1D variants, have also been associated with a predisposition to breast and ovarian cancer, highlighting a broader oncogenic influence. [27]
Association with Cardiovascular and Chronic Systemic Diseases
The clinical relevance of clonal hematopoiesis extends to a wide array of non-hematologic systemic diseases, particularly inflammatory and chronic conditions. CH is a recognized risk factor for atherosclerotic cardiovascular disease (CVD), with specific mutations contributing to inflammation that underlies cardiovascular pathology. [8] Beyond the cardiovascular system, CH has been associated with an increased risk of chronic kidney disease (CKD) and acute kidney injury, as well as chronic obstructive pulmonary disease (COPD) and emphysema. [35] Emerging evidence also links CH to chronic liver disease, including alcoholic liver disease, and an increased susceptibility to various types of infections. [36] Lifestyle factors such as smoking, high-fat diet, and alcohol intake are known to influence hematopoietic stem cell niches and are associated with specific CH mutations like ASXL1 variants, further underscoring the interplay between genetics, environment, and systemic health. [21]
Guiding Risk Stratification and Personalized Health Management
Understanding clonal hematopoiesis is crucial for advanced risk stratification and the development of personalized medicine approaches. Identifying individuals with CH, especially those carrying specific driver mutations such as in DNMT3A, TET2, ASXL1, SRSF2, or JAK2, allows for a more precise assessment of their risk for developing hematologic malignancies or other serious comorbidities. [7] This knowledge can inform targeted monitoring strategies, enabling earlier detection or intervention for high-risk individuals. Genetic factors, such as long telomere length alleles or specific polymorphisms like the IL6R variant, can influence CH development or attenuate its associated cardiovascular risks, suggesting potential avenues for personalized preventive or therapeutic strategies. [1] Comprehensive genomic profiling for CH, particularly in older individuals or those with other risk factors, holds promise for integrating this information into a holistic patient care model, optimizing health outcomes by identifying at-risk populations and guiding tailored interventions. [2]
Frequently Asked Questions About Clonal Hematopoiesis
These questions address the most important and specific aspects of clonal hematopoiesis based on current genetic research.
1. I'm getting older; is it normal for my blood to have these changes?
Yes, it is quite normal. Clonal hematopoiesis, which involves the expansion of specific blood cell lineages due to genetic alterations, is commonly observed as people age. In fact, it's considered ubiquitous in many healthy adults, meaning it's a very common finding, especially later in life.
2. Could I have this blood condition without feeling sick?
Yes, absolutely. Clonal hematopoiesis is very common in healthy adults, meaning many people have these changes in their blood without experiencing any symptoms or feeling ill. It's often discovered incidentally through genetic testing rather than clinical symptoms.
3. I have heart problems; could this blood change be linked?
Yes, there's a significant link. Clonal hematopoiesis has been found to increase your risk of developing atherosclerotic cardiovascular disease. So, these subtle genetic changes in your blood cells can indeed contribute to the development or progression of heart problems.
4. Does this mean I'm more likely to get cancer later?
It can increase your risk, yes. Clonal hematopoiesis is linked to a heightened risk of developing certain blood cancers, particularly myeloid leukemias. Specifically, changes in genes like DNMT3A are associated with a higher chance of developing these types of leukemias.
5. Does my family history increase my risk for these blood changes?
It can play a role. While the genetic changes in clonal hematopoiesis are typically somatic (meaning they arise during your lifetime), some individuals may have a genetic predisposition. For example, specific variations in genes like DNMT3A and TET2 can make you more susceptible to developing these clonal expansions.
6. Why do I seem to get sick with infections more often now?
Clonal hematopoiesis, especially certain forms involving mosaic chromosomal alterations in your blood cells, has been found to increase the risk for diverse types of infection. These changes can subtly impact your immune system's function, potentially making you more vulnerable to getting sick.
7. I've been feeling more tired lately; could this explain it?
It's a possibility. Clonal hematopoiesis is associated with an increased risk of cytopenias, which means having lower-than-normal counts of certain blood cells. Depending on which blood cells are affected, these lower counts could certainly contribute to symptoms like fatigue.
8. Can I do anything to prevent these blood changes from happening?
Research is ongoing to understand specific prevention strategies. While some changes arise from normal aging processes and DNA damage, understanding clonal hematopoiesis could lead to targeted prevention approaches in the future. For now, maintaining a healthy lifestyle is generally beneficial for overall health.
9. How would my doctor know if I have this condition?
Identifying clonal hematopoiesis typically involves specialized genetic testing of your blood cells. This testing looks for specific somatic alterations or "driver mutations" in key genes within your hematopoietic stem cells, revealing the presence of these expanded cell lineages.
10. I have a chronic condition; is there a link to these blood changes?
Yes, there can be. Clonal hematopoiesis has been linked to an increased risk or association with several chronic conditions, including acute kidney injury, chronic obstructive pulmonary disease (COPD), and chronic liver disease. It's an important area of research connecting aging, inflammation, and various long-term health issues.
This FAQ was automatically generated based on current genetic research and may be updated as new information becomes available.
Disclaimer: This information is for educational purposes only and should not be used as a substitute for professional medical advice. Always consult with a healthcare provider for personalized medical guidance.
References
[1] Stacey SN, et al. "Genetics and epidemiology of mutational barcode-defined clonal hematopoiesis." Nat Genet, 6 Nov. 2023.
[2] Kessler MD, et al. "Common and rare variant associations with clonal haematopoiesis phenotypes." Nature, vol. 612, 8 Dec. 2022, pp. 301–308.
[3] Young, A. L. et al. "Clonal haematopoiesis harbouring AML-associated mutations is ubiquitous in healthy adults." Nat Commun, vol. 7, 2016, p. 12484.
[4] Genovese, G. et al. "Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence." N. Engl. J. Med., vol. 371, 2014, pp. 2477–2487.
[5] Buscarlet, M. et al. "DNMT3A and TET2 dominate clonal hematopoiesis and demonstrate benign phenotypes and different genetic predispositions." Blood, vol. 130, 2017, pp. 753–762.
[6] McKerrell, T. et al. "Leukemia-associated somatic mutations drive distinct patterns of age-related clonal hemopoiesis." Cell Rep., vol. 10, 2015, pp. 1239–1245.
[7] Jaiswal, S. et al. "Age-related clonal hematopoiesis associated with adverse outcomes." N. Engl. J. Med., vol. 371, 2014, pp. 2488–2498.
[8] Jaiswal, S. et al. "Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease." N. Engl. J. Med., vol. 377, 2017, pp. 111–121.
[9] Vlasschaert, C. et al. "Clonal hematopoiesis of indeterminate potential is associated with acute kidney injury." Nat. Med., vol. 30, 2024, pp. 810–817.
[10] Miller, P. G. et al. "Association of clonal hematopoiesis with chronic obstructive pulmonary disease." Blood, vol. 139, 2022, pp. 357–368.
[11] Wong, T. N. et al. "Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia." Nature, vol. 518, 2015, pp. 552–555.
[12] Coombs, C. C. et al. "Therapy-related clonal hematopoiesis in patients with non-hematologic cancers is common and associated with adverse clinical outcomes." Cell Stem Cell, vol. 21, 2017, pp. 374–382.e4.
[13] Gibson, C. J. et al. "Clonal hematopoiesis associated with adverse outcomes after autologous stem-cell transplantation for lymphoma." J. Clin. Oncol., vol. 35, 2017, pp. 1598–1605.
[14] Zekavat, S. M. et al. "Hematopoietic mosaic chromosomal alterations increase the risk for diverse types of infection." Nat. Med., vol. 27, 2021, pp. 1012–1024.
[15] Jaiswal, S. & Libby, P. "Clonal haematopoiesis: connecting ageing and inflammation in cardiovascular disease." Nat. Rev. Cardiol., vol. 17, 2020, pp. 137–144.
[16] Ahmad, H., Jahn, N. & Jaiswal, S. "Clonal hematopoiesis and its impact on human health." Annu. Rev. Med., vol. 74, 2023, pp. 249–260.
[17] Kar SP, et al. "Genome-wide analyses of 200,453 individuals yield new insights into the causes and consequences of clonal hematopoiesis." Nat Genet, vol. 54, Aug. 2022, pp. 1155–1166.
[18] Wen S, et al. "Comparative analysis of the Mexico City Prospective Study and the UK Biobank identifies ancestry-specific effects on clonal hematopoiesis." Nat Genet, 26 Feb. 2024.
[19] King, K. Y., et al. "Environmental influences on clonal hematopoiesis." Experimental Hematology, vol. 83, 2020, pp. 66–73.
[20] Kaastrup, K. & Grønbæk, K. "The impact of sedentary lifestyle, high-fat diet, tobacco smoke, and alcohol intake on the hematopoietic stem cell niches." HemaSphere, vol. 5, 2021, e615.
[21] Dawoud, A. A. Z. et al. "Clonal myelopoiesis in the UK Biobank cohort: ASXL1 mutations are strongly associated with smoking." Leukemia, vol. 34, 2020, pp. 2660–2672.
[22] Cook, E. K., et al. "Clonal hematopoiesis and inflammation: partners in leukemogenesis and comorbidity." Experimental Hematology, vol. 83, 2020, pp. 85–94.
[23] Hong W, et al. "Clonal Hematopoiesis Mutations in Patients with Lung Cancer Are Associated with Lung Cancer Risk Factors." Cancer Res, vol. 82, no. 1, 1 Jan. 2022, pp. 111-120.
[24] Weinstock, J. S. et al. "Aberrant activation of TCL1A promotes stem cell expansion in clonal haematopoiesis." Nature, vol. 616, 2023, pp. 755–763.
[25] Munafò, M. R., et al. "Association between genetic variants on chromosome 15q25 locus and objective measures of tobacco exposure." Journal of the National Cancer Institute, vol. 104, no. 10, 2012, pp. 740–748.
[26] Ostrander, E. L. et al. "Divergent effects of Dnmt3a and Tet2 mutations on hematopoietic progenitor cell fitness." Stem Cell Rep., vol. 14, 2020, pp. 551–560.
[27] Ruark, E. et al. "Mosaic PPM1D mutations are associated with predisposition to breast and ovarian cancer." Nature, vol. 493, 2013, pp. 406–410.
[28] Sawai, C. M., et al. "Hematopoietic stem cells are the major source of multilineage hematopoiesis in adult animals." Immunity, vol. 45, no. 3, 2016, pp. 597–609.
[29] Kaasinen, Eeva, et al. "Impact of constitutional TET2 haploinsufficiency on molecular and clinical phenotype in humans." Nature Communications, vol. 10, no. 1, 2019, p. 1252.
[30] Bick, A. G. et al. "Genetic interleukin 6 signaling deficiency attenuates cardiovascular risk in clonal hematopoiesis." Circulation, vol. 141, 2020, pp. 124–131.
[31] Lim, Y., et al. "Integration of Hedgehog and mutant FLT3 signaling in myeloid leukemia." Science Translational Medicine, vol. 7, no. 291, 2015, p. 291ra96.
[32] Sperling, A. S. et al. "The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia." Nat. Rev. Cancer, vol. 17, 2017, p. 5.
[33] Moliterno, A. R., Ginzburg, Y. Z. & Hoffman, R. "Clinical insights into the origins of thrombosis in myeloproliferative neoplasms." Blood, vol. 137, 2021, pp. 1145–1153.
[34] Abelson, S. et al. "Prediction of acute myeloid leukaemia risk in healthy individuals." Nature, vol. 559, 2018, pp. 400–404.
[35] Dawoud, A. A. Z. et al. "Clonal myelopoiesis promotes adverse outcomes in chronic kidney disease." Leukemia, vol. 36, 2022, pp. 507–515.
[36] Wong, W. J. et al. "Clonal haematopoiesis and risk of chronic liver disease." Nature, vol. 616, 2023, pp. 747–754.